imsidolimab (ANB019) - AnaptysBio
Anti-IL-36 receptor treatment with imsidolimab shows promise for generalized pustular psoriasis, with 6 of 8 patients meeting the primary endpoint of this open label study in this month's @BrJDermatol : Aug 30, 2023 
https://twitter.com/BJDEditor/status/1696922014152306768
 
Aug 30, 2023
 
 
c9680406-6b9c-4183-9d84-3fd35723c269.jpg